[Form 4] Upstart Holdings, Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

Disc Medicine, Inc. (NASDAQ: IRON) – Form 144 filing overview

An insider—identified in the filing’s prior-sales table as Jean Franchi—has notified the SEC of an intention to sell 2,000 common shares of Disc Medicine. The shares will be routed through Morgan Stanley Smith Barney LLC on or about 10 July 2025. Based on the filing’s quoted price, the aggregate market value of the proposed sale is $111,720. The company has 34,634,000 shares outstanding; the proposed disposition therefore represents roughly 0.006 % of shares outstanding.

Acquisition background: The shares derive from restricted stock units (RSUs) granted on 15 Feb 2025. No cash payment was required when the RSUs were awarded.

Recent trading history: The same account executed a Rule 10b5-1 sale of 2,000 shares on 16 Jun 2025 for $104,518.80 in gross proceeds.

Key take-aways for investors:

• The filing is a routine Form 144 notice; it does not itself execute a sale but provides advance disclosure.
• The dollar amount is modest relative to Disc Medicine’s market capitalization and float, indicating limited direct market impact.
• Successive 2,000-share sales within a month may nevertheless be monitored as an insider-selling trend, especially if additional filings appear.

Positive

• None.

Negative

• Insider intends to sell 2,000 shares worth approximately $111,720 and has already sold 2,000 shares in June 2025, indicating continuing insider disposition.

Insights

Securities Analyst

TL;DR: Insider files to sell 2,000 IRON shares (~$112k); negligible size but follow insider-selling trend.

The Form 144 signals that insider Jean Franchi plans to dispose of 2,000 Disc Medicine shares—about six-thousandths of outstanding stock. A prior 2,000-share sale in June suggests a structured selling program, likely under a 10b5-1 plan. Given the tiny percentage and transparent advance notice, the filing is immaterial to valuation. However, consecutive sales can influence sentiment in thinly traded biotech names, so investors may wish to track future filings for escalation. No operational or financial data are included.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mirgorodskaya Natalia

(Last) (First) (Middle)

C/O UPSTART HOLDINGS, INC.

2950 S. DELAWARE STREET, SUITE 410

(Street)

SAN MATEO CA 94403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Upstart Holdings, Inc. [ UPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2025		M(1)		4,000	A	$25.9	28,623(2)	D
Common Stock	07/08/2025		S(1)		4,000	D	$80.0675(3)	24,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$25.9	07/08/2025		M(1)			4,000	(4)	08/31/2032	Common Stock	4,000	$25.9	3,677	D

Explanation of Responses:

1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2024.

2. Certain of these securities listed in Column 5 are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. 1/36th of the shares subject to the option shall vest on September 20, 2022 and at the end of each successive one-month period thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Chief Accounting Officer and Controller

	/s/ Jessica Jeong, by power of attorney	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Disc Medicine (IRON) disclose in the latest Form 144?

A notice that insider Jean Franchi plans to sell 2,000 common shares valued at $111,720 around 10 Jul 2025.

How large is the proposed insider sale relative to shares outstanding?

The 2,000 shares equal roughly 0.006 % of Disc Medicine’s 34.6 million shares outstanding.

Were there recent insider sales prior to this filing?

Yes. The same account sold 2,000 shares on 16 Jun 2025 for $104,518.80 in gross proceeds.

Is the Form 144 filing itself a sale?

No. Form 144 is a pre-sale notice; the actual transaction may occur on or after the listed approximate date.

Which broker will execute the sale?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.

What was the source of the shares to be sold?

They originated from restricted stock units granted on 15 Feb 2025.